{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:27:25Z","timestamp":1765758445110,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jaad.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T16:35:50Z","timestamp":1466008550000},"page":"525-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma"],"prefix":"10.1016","volume":"75","author":[{"given":"Susan M.","family":"Swetter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.05.010_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","article-title":"Performance of diagnostic\u00a0tests in an intensive follow-up protocol for AJCC stage IIB, IIC, and III patients with localized primary melanoma: a\u00a0prospective cohort study","volume":"75","author":"Podlipnik","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.05.010_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2016.05.010_bib3","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.05.010_bib4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1245\/s10434-007-9347-2","article-title":"Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines","volume":"14","author":"Francken","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jaad.2016.05.010_bib5","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/jdv.12602","article-title":"The utility of ancillary tests in monitoring cutaneous melanoma patients to detect visceral metastasis","volume":"29","author":"Ferreres","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.05.010_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/SLA.0000000000000233","article-title":"Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies","volume":"259","author":"Rueth","year":"2014","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.jaad.2016.05.010_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2014.03.001","article-title":"Follow-up of patients with early breast cancer: is it time to rewrite the story?","volume":"91","author":"Puglisi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.jaad.2016.05.010_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.bpobgyn.2014.04.008","article-title":"Which imaging technique should we use in the follow up of gynecological cancer?","volume":"28","author":"Testa","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"21","key":"10.1016\/j.jaad.2016.05.010_bib9","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1200\/JCO.2012.42.6189","article-title":"Who benefits from surveillance imaging?","volume":"30","author":"Armitage","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.05.010_bib10","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","article-title":"Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)","volume":"19","author":"Howard","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2016.05.010_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.2003.01.091","article-title":"Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy","volume":"21","author":"Garbe","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2016.05.010_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CMR.0b013e32833716f9","article-title":"Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?","volume":"20","author":"Leiter","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2016.05.010_bib13","unstructured":"National Comprehensive Cancer Network. Melanoma (version 2.2016). Available from: URL: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf. Accessed April 18, 2016."},{"issue":"5","key":"10.1016\/j.jaad.2016.05.010_bib14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaad.2011.04.031","article-title":"Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology","volume":"65","author":"Bichakjian","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"10.1016\/j.jaad.2016.05.010_bib15","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","article-title":"Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines","volume":"28","author":"Romano","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2016.05.010_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2016.05.010_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jaad.2016.05.010_bib18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jaad.2016.05.010_bib19","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaad.2016.05.010_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clon.2011.12.002","article-title":"Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline","volume":"24","author":"Petrella","year":"2012","journal-title":"Clin Oncol"},{"issue":"31","key":"10.1016\/j.jaad.2016.05.010_bib21","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2016.05.010_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.jaad.2016.05.010_bib23","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2013.53.1590","volume":"32","author":"Flaherty","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2016.05.010_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"J Eur J Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216302900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216302900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:37:38Z","timestamp":1759271858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216302900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0190962216302900"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.05.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1229","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}